- Home
- ABTC vs FOLD Comparison
ABTC vs FOLD Comparison
Compare ABTC & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTC | FOLD |
|---|---|---|
| Founded | 2024 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.5B |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | ABTC | FOLD |
|---|---|---|
| Price | $1.18 | $14.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $4.00 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 12.6M | 3.3M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $92.72 | $20.50 |
| Revenue Next Year | $40.46 | $18.59 |
| P/E Ratio | $5.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $5.66 |
| 52 Week High | $10.24 | $14.38 |
Technical Indicators
Market Signals| Indicator | ABTC | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 67.96 |
| Support Level | $0.93 | $14.21 |
| Resistance Level | $2.00 | $14.37 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 80.92 | 80.00 |
Price Performance
Historical ComparisonAbout ABTC American Bitcoin Corp.
American Bitcoin Corp is a Bitcoin accumulation platform focused on building America's Bitcoin infrastructure platform. The Company delivers institutional-grade exposure to Bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.